25 May 2013
Keywords: Eli Lilly, Bristol-Myers Squibb, Lung cancer, Necitumumab, Safety concerns
Article | 03 February 2011
US drug majors Eli Lilly (NYSE: LLY) and Bristol-Myers Squibb (NYSE: BMY) have stopped enrollment in one of their two ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 February 2011
2 February 2011
24 May 2013
© 2013 thepharmaletter.com